331. 特発性多中心性キャッスルマン病 Idiopathic multicentric castleman disease Clinical trials / Disease details

臨床試験数 : 33 / 薬物数 : 41 - (DrugBank : 21) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 123

3 trials found

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCT2071190029	25/05/2020	09/10/2019	Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resi ...	Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resi ...	idiopathic multicentric Castleman's disease Castleman's disease	Treatment: Sirolimus 2 mg po once/day. Control: Placebo given orally once daily	Kawakami Atsushi	NULL	Complete	>= 18age old	Not applicable	Both	20	Phase 2	Japan
2	NCT01441063 (ClinicalTrials.gov)	September 13, 2011	24/9/2011	Tocilizumab for KSHV-Associated Multicentric Castleman Disease	Pilot Study of Tocilizumabin Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - Associate ...	Castleman Disease;Multicentric Castleman Disease;Giant Lymph Node Hyperplasia	Drug: Zidovudine;Drug: Tocilizumab;Drug: Valganciclovir (VGC)	National Cancer Institute (NCI)	NULL	Completed	18 Years	N/A	All	8	Phase 2	United States
3	NCT01183598 (ClinicalTrials.gov)	August 2006	13/8/2010	A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease ...	Provision of Tocilizumabfor Patients With Multicentric Castleman's Disease Who Have Demonstrated Ben ...	Castleman's Disease	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	Both	3	Phase 1	United States

First Previous1Next Last